Why Amgen Stock Is Getting Hit by a Novartis Trial Setback - Barron's

As reported by Barron's

Amgen stock drops after Novartis’ disappointing trial results.

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on Barron's ↗

Market Samachar is a news aggregator. This article was originally published by Barron's. Tap the button above to read the full story on their site.

COMPANIES ICICI Prudential AMC gets RBI approval to buy up to 9.95% stake in Kotak and 3 other banks Stocks-Markets-Economic Times
INDIAN US stocks calm ahead of midterm polls, but markets may be underpricing the risk Markets-Economic Times
INDIAN RBL Bank raises $350 million in debut international bond sale Markets-Economic Times
INDIAN US stocks today: US stocks slide as oil tops $100, stoking fresh inflation fears Markets-Economic Times
INDIAN L&T, IIFL Finance follow REC into India's emerging tokenised bond market Share Market Today
INDIAN Sebi proposes easier director eligibility, norms for key MII officials Share Market Today
INDIAN Oil tops $100, rupee breaches 95/$ as stocks reel on US-Iran tensions Share Market Today
GLOBAL Air traffic failure was avoidable, says transport secretary BBC News

Why Amgen Stock Is Getting Hit by a Novartis Trial Setback - Barron's

More from Market Samachar